[Effectiveness of alizapride against emesis in infants and children (author's transl)].
The effectiveness of alizapride against vomiting was studied in a group of 40 patients including neonates, infants and children. Patients were hospitalized in a surgical ward. 2 to 8 mg/kg/24 h were given orally. Vomiting ceased in 75% of the cases. Optimal results were obtained with 4 to 5.6 mg/kg/24 h. With alizapride symptoms abated in all patients. Operative conditions were improved for those who needed surgery. In addition, nausea was relieved in 100% of cases and regurgitations in 67.7%. Our study shows that alizapride is a reliable drug with a short time lag and no side-effects. We conclude that it can be used against vomiting in pediatric patients.
D000293:Adolescent; D000932:Antiemetics / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009325:Nausea / Q000188:drug therapy*; D011759:Pyrrolidines / Q000008:administration & dosage*; D013535:Suspensions; D014839:Vomiting / Q000188:drug therapy*
D000932:Antiemetics; D011759:Pyrrolidines; D013535:Suspensions; C033968:alizapride
Les effets de l'alizapride dans les vomissements chez le nourrisson et l'enfant.